KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Capital Expenditures: 2009-2024

Historic Capital Expenditures for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $755.9 million.

  • Regeneron Pharmaceuticals' Capital Expenditures fell 16.74% to $201.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $849.3 million, marking a year-over-year increase of 5.15%. This contributed to the annual value of $755.9 million for FY2024, which is 5.19% up from last year.
  • According to the latest figures from FY2024, Regeneron Pharmaceuticals' Capital Expenditures is $755.9 million, which was up 5.19% from $718.6 million recorded in FY2023.
  • In the past 5 years, Regeneron Pharmaceuticals' Capital Expenditures ranged from a high of $755.9 million in FY2024 and a low of $551.9 million during FY2021.
  • Moreover, its 3-year median value for Capital Expenditures was $718.6 million (2023), whereas its average is $688.2 million.
  • Per our database at Business Quant, Regeneron Pharmaceuticals' Capital Expenditures spiked by 43.06% in 2020 and then decreased by 10.20% in 2021.
  • Yearly analysis of 5 years shows Regeneron Pharmaceuticals' Capital Expenditures stood at $614.6 million in 2020, then dropped by 10.20% to $551.9 million in 2021, then rose by 6.92% to $590.1 million in 2022, then increased by 21.78% to $718.6 million in 2023, then climbed by 5.19% to $755.9 million in 2024.